QQQ   423.60 (-0.87%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
QQQ   423.60 (-0.87%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
QQQ   423.60 (-0.87%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
QQQ   423.60 (-0.87%)
AAPL   181.46 (-0.06%)
MSFT   399.14 (-0.91%)
META   467.07 (-0.89%)
GOOGL   142.44 (+0.94%)
AMZN   167.91 (+0.50%)
TSLA   192.93 (-0.43%)
NVDA   669.65 (-3.58%)
NIO   6.04 (+1.34%)
AMD   163.61 (-1.26%)
BABA   75.92 (+3.80%)
T   16.97 (+0.35%)
F   12.11 (-1.14%)
MU   80.59 (-0.15%)
CGC   3.39 (-4.24%)
GE   148.27 (-0.24%)
DIS   107.82 (-1.48%)
AMC   4.58 (-1.72%)
PFE   27.51 (-0.29%)
PYPL   57.54 (-1.86%)
XOM   104.72 (+1.92%)
NASDAQ:HOLX

Hologic (HOLX) Stock Price, News & Analysis

$75.16
+0.58 (+0.78%)
(As of 01:33 PM ET)
Today's Range
$74.61
$75.41
50-Day Range
$70.32
$74.98
52-Week Range
$64.02
$87.88
Volume
648,295 shs
Average Volume
1.92 million shs
Market Capitalization
$17.64 billion
P/E Ratio
35.62
Dividend Yield
N/A
Price Target
$86.89

Hologic MarketRank™ Stock Analysis

Analyst Rating
Hold
2.38 Rating Score
Upside/​Downside
15.6% Upside
$86.89 Price Target
Short Interest
Healthy
1.94% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.59
Upright™ Environmental Score
News Sentiment
0.75mentions of Hologic in the last 14 days
Based on 11 Articles This Week
Insider Trading
Selling Shares
$2.35 M Sold Last Quarter
Proj. Earnings Growth
8.71%
From $4.02 to $4.37 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.65 out of 5 stars

Medical Sector

64th out of 932 stocks

X - Ray Apparatus & Tubes Industry

1st out of 4 stocks


HOLX stock logo

About Hologic Stock (NASDAQ:HOLX)

Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth. The company also offers breast cancer care solutions in the areas of radiology, breast surgery, pathology, and treatment, such as 3D digital mammography systems, image analytics software, reading workstations, minimally invasive breast biopsy guidance systems, breast biopsy site markers, localization, specimen radiology, and connectivity solutions; and breast conserving surgery products. In addition, it provides MyoSure Hysteroscopic Tissue Removal System for the removal of fibroids and polyps in the uterus; NovaSure Endometrial Ablation System to treat abnormal uterine bleeding; Fluent Fluid Management System that provides liquid distention during diagnostic and operative hysteroscopic procedures; Acessa ProVu system to treat various fibroids; and CoolSeal portfolio, such as bipolar vessel sealing devices. Further, the company offers Horizon DXA, a dual energy X-ray system; and Fluoroscan Insight FD mini C-arm to perform minimally invasive orthopedic surgical procedures. It sells its products through direct sales, service forces, independent distributors, and sales representatives. Hologic, Inc. was incorporated in 1985 and is headquartered in Marlborough, Massachusetts.

HOLX Stock Price History

HOLX Stock News Headlines

Hologic (NASDAQ:HOLX) Downgraded to Hold at StockNews.com
HOLX Mar 2024 50.000 put
Americans Now Favor Gold Over Stocks as an Investment Vehicle
Americans now consider gold a better long-term investment than stocks for the first time since 2013. But physical gold requires storage and insurance, and gold mining stocks come with significant risks. Fortunately, investors have found a little-known way to benefit from gold that avoids many of these challenges.
HOLX Mar 2024 70.000 put
Hologic, Inc.
Hologic: Prospects For Growth As Headwinds Disappear
Hologic First Quarter 2024 Earnings: Beats Expectations
An Unusual Way to Invest in Gold
Most financial experts recommend including gold in your investment mix to protect against rising prices and keep wealth secure. Investors are discovering a little-known way to benefit from gold, which offers the chance to gain from higher gold prices and mining successes while avoiding the costs of operating mines.
Hologic price target raised by $2 at Morgan Stanley, here's why
Hologic: Hold Rating Justified by Solid Performance and Fair Valuation
Q1 2024 Hologic Inc Earnings Call
Recap: Hologic Q1 Earnings
Hologic Inc Q1 Profit Increases, beats estimates
Hologic Q1 2024 Earnings Preview
Earnings Outlook For Hologic
See More Headlines
Receive HOLX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Hologic and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
2/01/2024
Today
2/21/2024
Next Earnings (Estimated)
5/06/2024
Fiscal Year End
9/30/2024

Industry, Sector and Symbol

Sector
Medical
Industry
X - ray apparatus & tubes
Sub-Industry
Health Care Equipment
Current Symbol
NASDAQ:HOLX
CUSIP
43644010
Employees
6,990
Year Founded
1985

Price Target and Rating

Average Stock Price Target
$86.89
High Stock Price Target
$105.00
Low Stock Price Target
$72.00
Potential Upside/Downside
+16.5%
Consensus Rating
Hold
Rating Score (0-4)
2.38
Research Coverage
8 Analysts

Profitability

Net Income
$456 million
Pretax Margin
15.83%

Debt

Sales & Book Value

Annual Sales
$4.03 billion
Cash Flow
$5.40 per share
Book Value
$19.83 per share

Miscellaneous

Free Float
230,624,000
Market Cap
$17.51 billion
Optionable
Optionable
Beta
1.02

Social Links

A Guide To High-Short-Interest Stocks Cover

MarketBeat's analysts have just released their top five short plays for March 2024. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Should I Buy Hologic Stock? HOLX Pros and Cons Explained

These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Hologic was last updated on Tuesday, February 20, 2024 at 3:25 PM.

Pros

Here are some ways that investors could benefit from investing in Hologic, Inc.:

  • Hologic, Inc. develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health, which is a growing market segment with increasing demand.
  • Recent developments in the company's product portfolio have shown innovation and competitiveness in the healthcare industry.
  • Hologic, Inc. has a strong distribution network that includes healthcare facilities, resources, independent distributors, and sales representatives, providing a wide reach for its products.
  • The current stock price of Hologic, Inc. is competitive and shows potential for growth based on recent financial performance.

Cons

Investors should be bearish about investing in Hologic, Inc. for these reasons:

  • While the company has shown innovation, there may be risks associated with new product development and market acceptance.














HOLX Stock Analysis - Frequently Asked Questions

Should I buy or sell Hologic stock right now?

8 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last twelve months. There are currently 5 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" HOLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in HOLX, but not buy additional shares or sell existing shares.
View HOLX analyst ratings
or view top-rated stocks.

What is Hologic's stock price target for 2024?

8 brokerages have issued 12 month price objectives for Hologic's shares. Their HOLX share price targets range from $72.00 to $105.00. On average, they expect the company's stock price to reach $86.89 in the next twelve months. This suggests a possible upside of 15.6% from the stock's current price.
View analysts price targets for HOLX
or view top-rated stocks among Wall Street analysts.

How have HOLX shares performed in 2024?

Hologic's stock was trading at $71.45 at the beginning of 2024. Since then, HOLX stock has increased by 5.2% and is now trading at $75.16.
View the best growth stocks for 2024 here
.

Are investors shorting Hologic?

Hologic saw a drop in short interest in the month of January. As of January 31st, there was short interest totaling 4,490,000 shares, a drop of 20.1% from the January 15th total of 5,620,000 shares. Based on an average daily trading volume, of 1,930,000 shares, the short-interest ratio is presently 2.3 days. Currently, 1.9% of the company's shares are short sold.
View Hologic's Short Interest
.

When is Hologic's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, May 6th 2024.
View our HOLX earnings forecast
.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) released its quarterly earnings results on Thursday, February, 1st. The medical equipment provider reported $0.98 EPS for the quarter, beating analysts' consensus estimates of $0.95 by $0.03. The medical equipment provider earned $1.01 billion during the quarter, compared to analysts' expectations of $989.32 million. Hologic had a net margin of 12.98% and a trailing twelve-month return on equity of 18.91%. The firm's revenue for the quarter was down 5.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.07 earnings per share.
Read the conference call transcript
.

What guidance has Hologic issued on next quarter's earnings?

Hologic issued an update on its FY 2024 earnings guidance on Thursday, February, 1st. The company provided earnings per share (EPS) guidance of 3.970-4.120 for the period, compared to the consensus estimate of 4.000. The company issued revenue guidance of $4.0 billion-$4.1 billion, compared to the consensus revenue estimate of $4.0 billion.

What is Steve MacMillan's approval rating as Hologic's CEO?

447 employees have rated Hologic Chief Executive Officer Steve MacMillan on Glassdoor.com. Steve MacMillan has an approval rating of 79% among the company's employees. 81.0% of employees surveyed would recommend working at Hologic to a friend.

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), NVIDIA (NVDA), Johnson & Johnson (JNJ), Alibaba Group (BABA), Walt Disney (DIS), PayPal (PYPL), Advanced Micro Devices (AMD), CVS Health (CVS), Pfizer (PFE) and Abbott Laboratories (ABT).

Who are Hologic's major shareholders?

Hologic's stock is owned by many different institutional and retail investors. Top institutional shareholders include Vanguard Group Inc. (11.79%), Victory Capital Management Inc. (2.15%), Price T Rowe Associates Inc. MD (1.51%), Norges Bank (1.30%), Parnassus Investments LLC (1.23%) and Northern Trust Corp (1.15%). Insiders that own company stock include Benjamin Jordan Cohn, Essex D Mitchell, Jan Verstreken, John M Griffin, Karleen Marie Oberton, Scott T Garrett, Sean S Daugherty and Sean S Daugherty.
View institutional ownership trends
.

How do I buy shares of Hologic?

Shares of HOLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Hologic have any subsidiaries?
The following companies are subsidiares of Hologic: Acessa Health, Acessa Health Inc., Beijing Hologic Technology Co. Ltd., Benassar Diagnostica-Equipamientos Medicos Unipessoal Lda., BioLucent, BioLucent LLC, Bioptics Inc., Biotheranostics Inc, Biotheranostics Inc., Bolder Surgical, Cynosure, Cytyc, Cytyc Corporation, Cytyc Prenatal Products Corp., Cytyc Surgical Products LLC, Diagenode Co. Ltd., Diagenode LLC, Diagenode SA, Diagenode SA., Diagenode SPA, Direct Radiography Corp., Emsor Sociedad de responsabilidad limitada, Faxitron Bioptics, Faxitron Bioptics LLC, Focal Therapeutics, Gen-Probe, Gen-Probe Incorporated, Gen-Probe Prodesse Inc., Gen-Probe Sales & Service Inc., Genewave SAS, Health Beacons Inc, Health Beacons Inc., Hologic (Australia & New Zealand) Pty Ltd., Hologic (MA) LLC, Hologic (Shanghai) Medical Supplies Co. Ltd., Hologic ASE LLC, Hologic Asia Limited, Hologic Asia Pacific Limited, Hologic Austria GmbH, Hologic BV, Hologic Bermuda Limited, Hologic Canada ULC, Hologic Caribbean (Barbados) SRL, Hologic Denmark ApS, Hologic Deutschland GmbH, Hologic Espana S.A., Hologic Finance Ltd., Hologic France SARL, Hologic GGO 2 LLC, Hologic GGO 3 LLP, Hologic GGO 4 LTD, Hologic Global Holding LTD, Hologic HUB LTD, Hologic Hitec-Imaging, Hologic Hitec-Imaging GmbH, Hologic Holdings Limited, Hologic IP LTD, Hologic Iberia S.L., Hologic India LLP, Hologic International Holdings B.V., Hologic Ireland Limited, Hologic Italia S.r.l., Hologic Japan KK, Hologic Latin America (Servicos Em Marketing E Negocios) Ltda., Hologic Ltd., Hologic Malaysia SDN. BHD., Hologic Medical Technologies (Beijing) Co. Ltd., Hologic Medicor GmbH, Hologic Medicor Suisse GmbH, Hologic Netherlands B.V., Hologic Nordic Holdings Oy, Hologic Singapore Pte. Ltd, Hologic Suisse SA, Hologic Surgical Products Costa Rica S.R.L., Hologic Sweden AB, Hologic Taiwan Ltd., Hologic UK Finance Ltd., Hologic US Finance Co LLC, Interlace Medical, Mobidiag Oy, Mobidiag Oy., Mobidiag UK Ltd., NXT-Dx SCRL, Navigation Three Limited, R2 Technology, Sentinelle Medical, Somatex (HK) Limited, Somatex Medical Technologies GmbH, Somatex Medical Technologies GmbH., Somatex USA Inc., SuperSonic Imagine (Shanghai) Medical Devices Co. Ltd., SuperSonic Imagine GmbH, SuperSonic Imagine HK Ltd, SuperSonic Imagine Ltd, SuperSonic Imagine SA, SuperSonic Imagine Srl, Suros Surgical Systems, Suros Surgical Systems Inc., TCT International, TCT International Co. Ltd., Third Wave Technologies, and Tridaho LLC.
Read More
This page (NASDAQ:HOLX) was last updated on 2/21/2024 by MarketBeat.com Staff